Precore and core promoter mutants are associated with higher  HBeAg  seroconversion but low disease remission rates in  HBV  patients treated with nucleos(t)ide analogues | Zendy

Zoutendijk R. | Zendy; Sonneveld M. J. | Zendy; Reijnders J. G. P. | Zendy; Vuuren A. J. | Zendy; Biesta P. | Zendy; Hansen B. E. | Zendy; Boonstra A. | Zendy; Janssen H. L. A. | Zendy

Premium

Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues

Author(s) -

Zoutendijk R.,

Sonneveld M. J.,

Reijnders J. G. P.,

Vuuren A. J.,

Biesta P.,

Hansen B. E.,

Boonstra A.,

Janssen H. L. A.

Publication year - 2013

Publication title -

journal of viral hepatitis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 100

eISSN - 1365-2893

pISSN - 1352-0504

DOI - 10.1111/jvh.12033

Subject(s) - seroconversion , hbeag , medicine , mutant , virology , gastroenterology , immunology , hepatitis b virus , biology , virus , gene , hbsag , genetics

Summary HBeAg seroconversion in HBV patients is considered an important event. We determined precore (PC) and base core promoter ( BCP ) mutations in 137 HBeAg ‐positive nucleos(t)ide analogues ( NA ) treated patients by INNO ‐ LiPA HBV P re C ore assay (Innogenetics). The majority of patients with nongenotype A had PC / BCP mutants present at baseline ( P = 0.02). During 29 months of therapy, 45 patients achieved HBeAg seroconversion. Probability of HBeAg seroconversion was higher in patients with PC and/or BCP mutants ( P = 0.01). After HBeAg seroconversion, patients with BCP mutants had more HBeAg relapse ( P = 0.07), and PC mutants less often achieved HBV DNA < 2000 IU/ mL ( P = 0.07).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research